This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (72)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Social Bookmarking   What's this?

Retrospective Analysis of 245 Episodes

Ioannis Chatzinikolaou, MD; Dima Abi-Said, PhD; Gerald P. Bodey, MD; Kenneth V. I. Rolston, MD; Jeffrey J. Tarrand, MD; George Samonis, MD, PhD

Arch Intern Med. 2000;160:501-509.

Background  Pseudomonas aeruginosa bacteremia is a serious and possibly fatal condition in patients with cancer.

Objectives  To ascertain the frequency, demographics, and predisposing factors for P aeruginosa bacteremia in patients with cancer and to determine the efficacy of various therapeutic regimens.

Subjects and Methods  Patient records of the Clinical Microbiology Laboratory, The University of Texas, M. D. Anderson Cancer Center, Houston, were reviewed. From January 1, 1991, through December 31, 1995, 245 eligible cases of P aeruginosa bacteremia were identified. We examined the patient records for the underlying malignant neoplasm and its management, symptoms and signs of infection, culture results of appropriate specimens, antibiotic therapy, and outcome. We also compared our present experience with a previous analysis from this institution covering the period from January 1, 1972, to December 31, 1981.

Results  The incidence of P aeruginosa bacteremia has decreased compared with the previous study (2.8 vs 4.7 cases per 1000 admissions). It was most common in patients with acute leukemia (55 of 1000 registrations), and the frequency in this disease has not changed. Half of the patients were not in the hospital when they developed their infection. The overall cure rate was 80%, which was a significant (P<.001) increase compared with the 62% cure rate in the previous study. In this study, no significant difference in the cure rates was observed between monotherapy with a -lactam and combination therapy overall (P = .72), and in patients with shock (P = 1.0) and those with pneumonia (P = .60). The patients' initial neutrophil counts were not of prognostic value; however, the cure rate depended on subsequent changes in neutrophil count during therapy.

Conclusions  The frequency rate of P aeruginosa bacteremia has decreased in patients with solid tumors but has remained unchanged in patients with acute leukemia. Antibiotic regimens for empirical therapy of neutropenic patients and especially patients with acute leukemia should still provide coverage against P aeruginosa.

From the Division of Medicine, Department of Medical Specialties, Section of Infectious Diseases (Drs Chatzinikolaou, Bodey, and Rolston), the Division of Surgery, Department of Neurosurgery (Dr Abi-Said), and the Division of Laboratory Medicine, Section of Clinical Microbiology (Dr Tarrand), The University of Texas, M. D. Anderson Cancer Center, Houston; and the Division of Medicine, University of Crete, Heraklion, Greece (Dr Samonis).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Archives of Internal Medicine Reader's Choice: Continuing Medical Education
Arch Intern Med. 2000;160(4):555-556.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Cost-effectiveness analysis of an antimicrobial stewardship team on bloodstream infections: a probabilistic analysis
Scheetz et al.
J Antimicrob Chemother 2009;63:816-825.
ABSTRACT | FULL TEXT  

Infections in AIDS Patients and Other Immunocompromised Hosts
Karam
ACCP Crit Care Med Brd Rev 2009;20:13-40.
FULL TEXT  

Successful treatment of multi-resistant Pseudomonas aeruginosa osteomyelitis after allogeneic bone marrow transplantation with a combination of colistin and tigecycline
Stanzani et al.
J Med Microbiol 2007;56:1692-1695.
ABSTRACT | FULL TEXT  

High-Throughput Screens for Small-Molecule Inhibitors of Pseudomonas aeruginosa Biofilm Development
Junker and Clardy
Antimicrob. Agents Chemother. 2007;51:3582-3590.
ABSTRACT | FULL TEXT  

Impact of Empiric Antibiotic Therapy on Outcomes in Patients with Pseudomonas aeruginosa Bacteremia
Osih et al.
Antimicrob. Agents Chemother. 2007;51:839-844.
ABSTRACT | FULL TEXT  

Impact of inactive empiric antimicrobial therapy on inpatient mortality and length of stay.
Scarsi et al.
Antimicrob. Agents Chemother. 2006;50:3355-3360.
ABSTRACT | FULL TEXT  

Pathogen-Host Interactions in Pseudomonas aeruginosa Pneumonia
Sadikot et al.
Am. J. Respir. Crit. Care Med. 2005;171:1209-1223.
ABSTRACT | FULL TEXT  

Pseudomonas aeruginosa Bloodstream Infection: Importance of Appropriate Initial Antimicrobial Treatment
Micek et al.
Antimicrob. Agents Chemother. 2005;49:1306-1311.
ABSTRACT | FULL TEXT  

Virulence of Pseudomonas aeruginosa in a Murine Model of Gastrointestinal Colonization and Dissemination in Neutropenia
Koh et al.
Infect. Immun. 2005;73:2262-2272.
ABSTRACT | FULL TEXT  

Predictive value of isolating Pseudomonas aeruginosa from aerobic and anaerobic blood culture bottles
Enoch et al.
J Med Microbiol 2004;53:1151-1154.
ABSTRACT | FULL TEXT  

Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis
Zelenitsky et al.
J Antimicrob Chemother 2003;52:668-674.
ABSTRACT | FULL TEXT  

Effectiveness of Combination Antimicrobial Therapy for Pseudomonas aeruginosa Bacteremia
Chamot et al.
Antimicrob. Agents Chemother. 2003;47:2756-2764.
ABSTRACT | FULL TEXT  

Consumption of Imipenem Correlates with {beta}-Lactam Resistance in Pseudomonas aeruginosa
Lepper et al.
Antimicrob. Agents Chemother. 2002;46:2920-2925.
ABSTRACT | FULL TEXT  

A clinical index predicting mortality with Pseudomonas aeruginosa bacteraemia
ALIAGA et al.
J Med Microbiol 2002;51:615-701.
ABSTRACT | FULL TEXT